Organon reports Q2 EPS $1.31 , consensus 97c

Reports Q2 revenue $1.61B , consensus $1.56B. “During the second quarter of 2023, Organon continued to build on its track record, delivering solid volume growth across all regions and franchises. The Women’s Health and Biosimilars franchise revenue grew 10% and 15% excluding the impact of foreign currency , respectively, and Established Brands continued to demonstrate stability,” said Kevin Ali, Organon’s CEO. “Further, on July 1st we launched Hadlima in the United States – so far our biggest commercial launch in the U.S. as a standalone company. Hadlima is emerging as one of a few biosimilars offerings earning commercial success so far. We are encouraged by our early traction and remain confident in our strategy, the attributes of our product and our collaborator’s capabilities to deliver reliable supply.”